Premenstrual dysphoric disorder

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Martedì, Giugno 11, 2024

In the fourth quarter of fiscal 2024, Vistagen launched its PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of SAD.

Key Points: 
  • In the fourth quarter of fiscal 2024, Vistagen launched its PALISADE-3 Phase 3 trial of fasedienol for the acute treatment of SAD.
  • In the first quarter of fiscal 2024, Vistagen announced favorable safety and tolerability data from its U.S.
  • In the second quarter of fiscal 2024, Vistagen announced the appointment of Cindy Anderson as Chief Financial Officer.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Retrieved on: 
Martedì, Aprile 9, 2024

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
  • Title: PH80 Nasal Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: Results from a Phase 2a Study
    The posters will be available on the Publications page of Vistagen’s website on Monday, April 15, 2024.
  • In addition to presenting fasedienol and PH80 clinical data, Vistagen will receive the ADAA 2024 Partner Recognition Award, recognizing Vistagen as a partner organization that has consistently contributed to the success of ADAA’s annual conference and supported ADAA’s public and professional mission.
  • Vistagen and ADAA are committed to redefining the future of mental health care and bringing hope to millions of individuals affected by debilitating mental health disorders.

Perinatal depression linked with premenstrual mood disorders – new research

Retrieved on: 
Venerdì, Aprile 5, 2024

But for the millions of women who have a premenstrual disorder, such as severe premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), these mood changes can be far more severe than normal.

Key Points: 
  • But for the millions of women who have a premenstrual disorder, such as severe premenstrual syndrome (PMS) or premenstrual dysphoric disorder (PMDD), these mood changes can be far more severe than normal.
  • Premenstrual disorders manifest through a range of symptoms – including mood swings, irritability and fatigue.
  • Our study found that women who have a premenstrual disorder may also be at greater risk of depression during or after pregnancy.
  • Having a premenstrual disorder may also partly explain why mental health problems may be more common in young women.

Perinatal depression

  • The hormonal fluctuations that happen during and after pregnancy can also precipitate a unique form of turmoil: perinatal depression.
  • Historically, the threads connecting premenstrual disorders and perinatal depression have been recognised anecdotally.
  • We revealed that women with a history of premenstrual disorders are five times more susceptible to developing perinatal depression if they become pregnant.
  • Read more:
    Maternal mental health problems – the impact in numbers

    Moreover, our study is the first to draw connections not just to postnatal depression (depression after childbirth) but also antenatal depression (depression during pregnancy).

  • We also showed that women who experience perinatal depression are at a higher risk of encountering premenstrual disorders later on.

Advocate for mental health

  • It also suggests that women with a history of premenstrual disorders should be closely screened for perinatal depression, and provided with the help and resources they may need for their mental health before and during pregnancy, and just after giving birth.
  • Moreover, it encourages women themselves to advocate for their mental health, armed with the understanding that their experiences before and during pregnancy are not isolated – but part of a broader hormonal narrative that needs addressing.


Donghao Lu receives funding from the Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and Karolinska Institutet.

Menstrual health literacy is alarmingly low – what you don’t know can harm you

Retrieved on: 
Mercoledì, Marzo 13, 2024

When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.

Key Points: 
  • When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.
  • If given multiple choice options, most think that periods either “clean the womb” or somehow “help prepare for pregnancy”.
  • Yes, the blood part can stain clothing, but there is nothing pathological, contaminating, or dangerous about periods.

So, why do we have periods?

  • Periods likely evolved as a kind of preemptive abortion, to protect women from unviable or dangerous pregnancies.
  • As a result, we have low rates of conception, high rates of miscarriage, and extremely high rates of maternal mortality in comparison to other mammals.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.
  • The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.

What else don’t we know?

  • Perhaps with the fact that the second phase of the cycle from ovulation to menstruation is a series of highly inflammatory processes.
  • This was only very briefly mentioned in three out of 16 textbooks.
  • We really ought to be taught from puberty how to reduce period pain and blood loss – this is not difficult science.

Why aren’t we taught this stuff?

  • My research shows that the exclusive focus on the female sex hormones in menstrual education is informed by societal influences, such as the myth of the hysterical or hormonal female.
  • This gender myth is still alive and well, although now we tend to blame the (female sex) hormones.
  • Again, there was no scientific reason for this change in focus, although it reflected existing societal beliefs about the inherently irrational behaviour of women.
  • Unfortunately, menstrual health literacy has not yet recovered from this shift in physiological models.

So what?

  • It also becomes much easier to differentiate premenstrual changes from underlying health conditions, since the latter will not be substantially alleviated by anti-inflammatory interventions alone.
  • Teaching the reductive hormonal model of the menstrual cycle unintentionally provides pseudo-scientific evidence for the damaging hormonal or hysterical female gender myth.


Sally King is the founder of Menstrual Matters- the world's first evidence-based info hub on menstrual health and rights www.menstrual-matters.com. Her doctoral research and current research fellowship were funded by the ESRC (Economic and Social Research Council).

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Martedì, Febbraio 13, 2024

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
  • As of February 12, 2024, the Company had 27,029,731 shares of common stock issued and 3,577,240 pre-funded warrants outstanding.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
  • In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, February 13, 2024.

Emerging Filmmaker, Mirejah Cruz, Garners Acclaim for Award-Winning Short Film "Hell Week"

Retrieved on: 
Mercoledì, Febbraio 7, 2024

LOS ANGELES, Feb. 7, 2024 /PRNewswire/ -- Mirejah Cruz, an up-and-coming actor and filmmaker, is rapidly gaining recognition for her groundbreaking work in the industry. Her latest project, the award-winning short film Hell Week, has captivated audiences and critics alike with its poignant exploration of Premenstrual Dysphoric Disorder (PMDD).

Key Points: 
  • Her latest project, the award-winning short film Hell Week, has captivated audiences and critics alike with its poignant exploration of Premenstrual Dysphoric Disorder (PMDD).
  • The film has resonated deeply with viewers, sparking important conversations about mental health, women's experiences and the medical industry.
  • The film's impact is undeniable, with Hell Week already selected for participation in eight prestigious film festivals, including the California Women's Film Festival and the London International Short Film Festival.
  • Hell Week is directed by Kassandra Mahea, written by Mirejah Cruz and produced by Damon Cirulli and Mirejah Cruz.

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results

Retrieved on: 
Giovedì, Novembre 9, 2023

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 second quarter ended September 30, 2023.
  • To complement the positive top-line results from PALISADE-2, the Company is preparing to launch two similar Phase 3 clinical trials in 2024, PALISADE-3 in the first half of 2024 and PALISADE-4 in the second half of 2024.
  • She joins Vistagen from Alnylam Pharmaceuticals where she served as the Chief Accounting Officer, focused on strategic and financial operations.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Retrieved on: 
Martedì, Settembre 12, 2023

At the second study visit, subjects were randomized to receive a single dose of 0.9 µg PH80 nasal spray or placebo in the clinic.

Key Points: 
  • At the second study visit, subjects were randomized to receive a single dose of 0.9 µg PH80 nasal spray or placebo in the clinic.
  • The previously unreported results of this exploratory Phase 2A clinical study of PH80 signal a potential revolutionary method for treating premenstrual mood symptoms,” said Shawn Singh, Chief Executive Officer of Vistagen.
  • “PMDD symptoms can be extremely limiting to daily functioning and PH80 demonstrated the potential to alleviate these symptoms.
  • Vistagen gained access to the results of the study in connection with its acquisition of Pherin in February 2023.

Curio Digital Therapeutics Wins Most Innovative Company Award at BioNJ’s Biopartnering Conference

Retrieved on: 
Giovedì, Giugno 29, 2023

Curio Digital Therapeutics, a digital therapeutics company focused on supporting women across the cycle of life, announced today that it has won the Most Innovative Company Award at BioNJ’s 12th Annual BioPartnering Conference.

Key Points: 
  • Curio Digital Therapeutics, a digital therapeutics company focused on supporting women across the cycle of life, announced today that it has won the Most Innovative Company Award at BioNJ’s 12th Annual BioPartnering Conference.
  • The BioPartnering Conference, held on May 9-11, 2022, brought together life sciences professionals from around the world to network, collaborate and showcase their innovative solutions.
  • Curio was selected as the winner of the Most Innovative Company Award by a panel of judges based on market opportunity, unmet need, overall innovation, differentiation and IP.
  • “We congratulate Curio on winning the Most Innovative Company Award and commend them for their dedication to improving the lives of women through their cutting-edge digital therapeutics solutions.”
    Curio Digital Therapeutics is a digital therapeutics company focused on supporting women across the cycle of life.

Thirty Madison names Caroline Hofmann Chief Business Officer to oversee the telehealth leader's continued expansion into women's specialty healthcare

Retrieved on: 
Mercoledì, Maggio 17, 2023

NEW YORK, May 17, 2023 /PRNewswire/ -- Thirty Madison, the specialty care company improving access, affordability, outcomes, and patient experience, has named Caroline Hofmann its chief business officer. In her new role, Hofmann will oversee all Thirty Madison businesses, lead the continued expansion of its women's health portfolio under Nurx, and focus on developing strategies that will improve patient outcomes and experiences while delivering on the company's path to profitability.

Key Points: 
  • Hofmann will oversee all Thirty Madison businesses, lead expansion in women's health, and develop business strategies to reach profitability
    NEW YORK, May 17, 2023 /PRNewswire/ -- Thirty Madison , the specialty care company improving access, affordability, outcomes, and patient experience, has named Caroline Hofmann its chief business officer.
  • Formerly head of emerging businesses, Hofmann led the expansion of Nurx into new condition offerings to treat more women holistically across reproductive care, sexual health, dermatology, and mental health.
  • As chief business officer, Hofmann will oversee and lead operations of all Thirty Madison business lines, ensuring patient experience remains at the center of its broad range of offerings.
  • Hofmann joined Thirty Madison from Republic, a platform that democratizes access to private investments, where she served as Chief Operating Officer.